Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Memphasys Ltd ( (AU:MEM) ) has issued an announcement.
Memphasys Limited has requested a trading halt on its securities pending an announcement regarding the results of its 2-year Felix™ System clinical trial. The trading halt is intended to ensure an orderly market, and the company expects to release the announcement before the commencement of trading on March 24, 2025.
More about Memphasys Ltd
Memphasys Limited operates in the biotechnology industry, focusing on reproductive biotechnology solutions. The company’s primary product is the Felix™ System, which is designed to enhance sperm selection for assisted reproductive technologies.
Average Trading Volume: 10,181,599
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: A$12.4M
See more insights into MEM stock on TipRanks’ Stock Analysis page.